MIAMI OL20 11
Alternative Names: MIAMI-OL20-11Latest Information Update: 30 Apr 2021
Price :
$50 *
At a glance
- Originator French National Public Institute for Agronomic Research; Olmix Group
- Developer OLGRAM
- Class Anti-infectives; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Nosocomial infections
Most Recent Events
- 06 Apr 2021 Olgram plans a phase II trial in 2026 (Olgram pipeline, April 2021)
- 06 Apr 2021 Olgram in-licenses MIAMI-OL20-11 from Olmix group and French National Public Institute for Agronomic Research (INRAe) (Olgram pipeline, April 2021)
- 06 Apr 2021 Olgram plans a phase I trial in 2025 (Olgram pipeline, April 2021)